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The Need for New Antiviral 
Therapies
Viruses are formidable targets for drug 
development. As obligate intracellular 
parasites that take over the host 
cellular machinery to further their own 
agenda, they seem to understand the 
intimate workings of cellular pathways 
better than those seeking to develop 
treatments against them. It is difﬁ  cult 
to inactivate a virus without doing harm 
to the host cell. 
Only in the past decade with the 
concerted efforts to control the HIV/
AIDS epidemic have antiviral drugs 
come into their own. By targeting viral 
proteins and pathways unique to the 
viral life cycle, it has become possible 
to interfere with viral infection and 
replication for a few viruses without 
unacceptable host cell toxicity. 
However, antiviral drugs have only 
been developed for a handful of 
viruses, and none of these antiviral 
drugs is completely effective. Viral 
resistance, sequence diversity, and drug 
toxicity are signiﬁ  cant problems for all 
antiviral therapies. In this article, we 
discuss recent progress and obstacles 
to harnessing RNA interference to 
prevent or treat viral infection.
HIV-1 and hepatitis B and C 
virus infections are responsible 
for signiﬁ  cant global epidemics. 
Moreover, there is no treatment for 
most acute viral infections, including 
ones that cause hemorrhagic fever, 
encephalitis, and death. The prospect 
of global pandemics caused by newly 
emerging infections, such as SARS 
coronavirus or avian inﬂ  uenza, in 
the setting of economic development 
and changing ecology, has made the 
rapid development of novel antiviral 
therapies an international priority. It 
is not surprising, then, that as soon 
as RNA interference (RNAi) was 
discovered to work in mammalian 
cells, researchers honed in on attempts 
to harness this ancient antiviral 
mechanism to prevent or treat viral 
infection.
How RNAi Works
RNAi uses small double-stranded 
RNAs to silence genes bearing a 
complementary sequence. Although 
endogenous gene silencing operates 
through multiple mechanisms, 
including mRNA cleavage, inhibition 
of translation, and epigenetic 
modiﬁ  cations of chromatin, mRNA 
cleavage is the most efﬁ  cient 
mechanism and is the mechanism 
being harnessed for antiviral therapies. 
Small RNAs, either exogenous 
small interfering RNAs (siRNAs) or 
endogenous microRNAs, are taken up 
by a cytoplasmic RNA-induced silencing 
complex (RISC), which cleaves one 
strand, leaving the remaining unpaired 
guide strand to search for mRNAs 
bearing complementary sequences. 
Once recognized, if the target site 
on the mRNA has nearly perfect 
complementarity to the guide siRNA, 
the mRNA is cut by an Argonaute 
endonuclease in the RISC and then 
degraded, silencing the expression 
of the protein it encodes. Typically 
protein expression is reduced but not 
completely eliminated. The RNAi 
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•  Gitlin L, Karelsky S, Andino R (2002) 
Short interfering RNA confers 
intracellular antiviral immunity in 
human cells. Nature 418: 430–434. 
An early paper that showed in vitro 
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viruses by nasally administered 
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and in vivo effectiveness of nasally 
administered uncomplexed siRNAs 
for the clinically important respiratory 
syncytial virus.
•  Li BJ, Tang Q, Cheng D, Qin C, Xie FY, et 
al. (2005) Using siRNA in prophylactic 
and therapeutic regimens against 
SARS coronavirus in Rhesus macaque. 
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to show therapeutic efﬁ  cacy of siRNAs 
in a nonhuman primate to treat 
respiratory infection by the SARS 
coronavirus. 
•  Palliser D, Chowdhury D, Wang QY, Lee 
SJ, Bronson RT, et al. (2006) An siRNA-
based microbicide protects mice from 
lethal herpes simplex virus 2 infection. 
Nature 439: 89–94. A study that shows 
the potential for vaginal application 
of siRNAs to prevent or treat sexually 
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machinery is present in all cells, where 
it is used to regulate the expression of 
key genes involved in cell development, 
differentiation, and survival. Small 
RNAs can be readily designed to target 
any gene, whether an endogenous 
host gene or foreign viral gene. For 
example, for HIV virtually all of the 
nine HIV gene products have been 
shown to be capable of being silenced, 
and siRNAs targeting the viral long 
terminal repeat are also effective 
(Figure 1).
RNAi Is an Ancient Antiviral 
Defense
In organisms that lack an adaptive 
immune response to pathogens, RNAi 
is an important defense against viral 
infection. In plants and ﬂ  atworms, the 
genes encoding key RNAi pathway 
endonucleases Dicer and Argonaute 
have developed into gene families. 
These families may have evolved 
to provide molecules dedicated 
to controlling viral infection and 
preventing chromosomal insertion 
of rogue genetic elements, such 
as transposons, to supplement the 
activities of other homologous RNAi 
molecules required for regulating 
endogenous gene expression. Over 
90% of plant viruses use double-
stranded RNA at some point in their 
life cycle, making them especially 
vulnerable to Dicer cleavage and 
suppression by RNAi. Plant viruses have 
developed mechanisms to bypass RNAi, 
most prominently by synthesizing 
viral proteins that bind and sequester 
siRNAs; other mechanisms have been 
described and additional ones are still 
being uncovered. 
Although the importance of 
RNAi in antiviral defense has been 
clearly shown in plants, worms, and 
ﬂ  ies, whether or not mammals use 
RNAi to defend against viruses is 
still uncertain, but likely. Several 
mRNAs encoded by a primate 
retrovirus contain complementary 
sequences that are targeted by an 
endogenous microRNA. Moreover 
viral variants with a mutated target 
sequence replicate more efﬁ  ciently. 
Several examples of mammalian virus 
strategies for interfering with RNAi 
have been described, suggesting the 
viruses are trying to bypass an antiviral 
host response [1]. One strategy, 
analogous to the suppression of 
silencing exhibited by plant viruses, is 
elaboration of proteins, such as NS1 
of inﬂ  uenza and E3L of vaccinia, that 
bind to and inactivate double-stranded 
RNAs. Another strategy, employed by 
adenovirus, is copious expression of a 
microRNA that binds to and inactivates 
the microRNA export and Dicer 
processing machinery. 
Mammalian viruses also take 
advantage of RNAi to carry out their 
replication strategies. In particular, 
several herpesviruses encode 
microRNAs that seem to be involved 
in regulating viral latency. Viruses may 
use microRNAs to regulate sequential 
patterns of gene expression much 
like other organisms use microRNAs 
to regulate key genes that determine 
progression from one developmental 
state to another. SV40-encoded 
microRNAs direct the cleavage of 
early SV40 transcripts, which encode 
T antigens [2]. Hepatitis C virus 
makes use of the microRNA miR-
122, which is efﬁ  ciently expressed in 
liver cells and matches a sequence 
in the viral 5′ untranslated region, 
to promote its replication [3]. Since 
viruses have evolved to exploit intrinsic 
host molecular pathways to promote 
their own replication, they will be 
an important tool for probing how 
microRNAs regulate gene expression 
even in uninfected cells. Interfering 
with either virally encoded or host 
microRNAs required for efﬁ  cient viral 
replication may provide a novel strategy 
for antiviral therapeutics. A recent 
study shows the feasibility of inhibiting 
microRNA function in vivo using 
cholesterol-conjugated 2′-O-methyl 
siRNAs [4].
Guiding Principles for Choosing 
siRNAs to Suppress Viruses
RNAi can be used to suppress viral 
replication by targeting either viral 
genes or host genes needed for viral 
replication. Silencing viral genes 
such as viral polymerases or master 
regulators of viral gene transcription 
(which are essential for fundamental 
viral processes), or silencing viral genes 
that act early in the viral life cycle, 
may more effectively suppress viral 
replication than targeting late genes 
or accessory viral genes that contribute 
to pathogenesis (but that are not vital 
for viral replication). In vitro studies 
have shown the usefulness of RNAi in 
DOI: 10.1371/journal.pmed.0030242.g001
Figure 1. Possible Targets for Suppressing HIV Replication
siRNAs can be used to silence either viral mRNAs or host genes required for viral entry or 
replication. This ﬁ  gure shows some possible targets for suppressing HIV replication. Silencing CCR5 
can prevent viral entry, while any viral gene can also be silenced to interfere with viral production. 
siRNAs could also target the viral long term repeat or even the proviral genomic RNA prior to 
integration, although whether this can be done is controversial. Targeting multiple genes will 
enhance viral suppression and reduce the chances of viral escape by sequence mutation.
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vitro to suppress virtually every class 
of virus, whether a virus uses double-
stranded, single-positive, or negative-
strand RNA or DNA for its genome. 
Algorithms for siRNA or short hairpin 
RNA (shRNA) design provide guidance 
for designing effective sequences, but 
this process is imperfect (with a success 
rate of over 60%). The algorithms 
do not predict which sequences will 
be most effective at silencing their 
target gene. Nor do they predict which 
sequences maximize viral inhibition 
and minimize sequence-speciﬁ  c off-
target effects arising from unintended 
silencing of partially homologous genes 
or from sequence-speciﬁ  c binding 
to Toll-like receptors, which triggers 
an inﬂ  ammatory response. The best 
candidate siRNA sequences need to 
be determined by experiment. Off-
target silencing of genes with partial 
homology is impossible to avoid 
because inhibition of translation may 
involve complementarity to just a 
seven-nucleotide stretch of the siRNA. 
However, translational inhibition 
generally has only a small impact on 
gene expression, can be minimized 
by avoiding sequences that target 
important genes, and is unlikely to 
be an important impediment to the 
clinical use of RNAi, although clinically 
signiﬁ  cant toxicity from off-target 
effects will be difﬁ  cult to predict in 
advance. Off-target effects caused by 
incorporation of the passenger strand, 
instead of the antisense strand, of the 
siRNA into RISC can be avoided by 
designing the siRNA ends to favor 
RISC uptake by the intended active 
strand.
Addressing the Obstacles of Viral 
Sequence Diversity and Escape 
Mutation
Important obstacles to using RNAi 
as the active principle for antiviral 
treatments are the related issues of viral 
sequence diversity and potential viral 
escape from gene silencing by sequence 
mutation. RNA viruses, such as 
poliovirus or HIV, may be particularly 
susceptible to escape mutation because 
of the low ﬁ  delity with which their 
genomes are replicated [5,6]. These 
problems can be circumvented by 
silencing host genes required for viral 
entry or replication. 
However, targeting host genes may 
lead to unacceptable host cell toxicity, 
unless RNAi can be selectively induced 
only in infected cells or transiently 
in vulnerable subsets of cells. This 
might be achieved by targeting siRNAs 
exclusively into vulnerable cells or by 
regulating expression of shRNAs by 
using an inducible promoter that is 
activated by a viral gene product. A 
recent strategy that uses an antibody 
fragment fusion protein to bind and 
deliver siRNAs only into cells bearing 
the cell surface receptor recognized by 
the antibody can deliver siRNAs and 
silence gene expression speciﬁ  cally in 
HIV-infected cells [7]. Expression of 
an shRNA designed to silence a host 
protein required for HIV replication 
might be induced only upon HIV 
infection by using a TAT-dependent 
promoter [8]. For HIV infection, 
the viral coreceptor CCR5 might be 
an exceptional host gene that can 
be silenced without toxicity, since 
individuals homozygous for a genetic 
mutation that functionally inactivates 
CCR5 are completely asymptomatic. 
Since the morbidity and mortality 
associated with many viral infections 
may be secondary to stereotypic overly 
exuberant inﬂ  ammatory or immune 
responses, silencing host genes 
proximal in these pathways provides 
another possible type of intervention. 
For example, hepatitis B and C are not 
cytopathic viruses, but trigger hepatitis 
when activated immune cells expressing 
FasL inﬁ  ltrate the liver, where the 
infection upregulates the death 
receptor Fas on hepatocytes, making 
them prime targets for immune-
mediated apoptosis. Silencing Fas in 
hepatocytes or FasL in immune cells 
might provide an effective immune-
modulating therapy to circumvent 
chronic liver cell damage [9].
DOI: 10.1371/journal.pmed.0030242.g002
Figure 2. siRNA Antiviral Therapy in Animal Models
(A) Intravaginal application of siRNAs mixed with a transfection lipid inhibits sexual transmission of 
HSV-2 in mice [17].
(B) Intranasal or intratracheal administration of siRNAs, either by themselves or mixed with lipids, 
protects against respiratory infection in mice [12,13,15].
(C) Intranasal administration of siRNAs in rhesus macaques protects against SARS coronavirus 
infection [16].
(D) Intravenous injection of siRNAs incorporated into specialized liposomes inhibits a hepatitis B 
virus replicon [19].
(E) Intracerebral injection of siRNAs protects against ﬂ  avivirus encephalitis [10].
HSV-2, herpes simplex virus type 2; HBV, hepatitis B virus; HCV, hepatitis C virus; RSV, respiratory 
syncytial virus.
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When viral genes are targeted, the 
related problems of viral sequence 
diversity and potential escape mutation 
can be circumvented by choosing 
highly conserved sequences whose 
mutation might result in impaired 
viral ﬁ  tness. This may be possible even 
for a highly diverse and mutation-
prone virus, like HIV, in which many 
short sequences are conserved even 
at the nucleotide level. By targeting 
a highly conserved HIV vif sequence, 
researchers were able to suppress a 
variety of primary viral isolates chosen 
at random to represent ﬁ  ve distinct 
viral clades [10]. In a recent study by 
Kumar and colleagues published in 
PLoS Medicine, a sequence conserved 
among a variety of ﬂ  aviviruses silenced 
both Japanese encephalitis virus and 
West Nile virus [11]. 
Another approach for preventing 
viral escape mutation is to combine 
siRNAs targeting multiple genes, 
much as effective drug therapy for 
HIV requires combining antiviral 
drugs targeting different steps in HIV 
replication. For the encephalitis viruses, 
Kumar and colleagues’ study suggests 
it might be possible to administer a 
cocktail of siRNAs that could effectively 
suppress a variety of likely suspect 
viruses before a deﬁ  nitive diagnosis 
is made, thus avoiding a dangerous 
delay in treatment. For any particular 
virus, a cocktail of siRNAs targeting 
viral and host genes whose products 
act at different points in the viral life 
cycle is likely to act synergistically 
to suppress viral replication more 
effectively and hence reduce the 
chance of viral escape mutation [12]. 
However, the cellular RNAi machinery 
has limited capacity since silencing 
can be suppressed by an excess of 
irrelevant double-stranded small 
RNAs, a strategy used by adenovirus 
for suppressing RNAi [13]. Similarly, 
gene therapy vectors that express 
high amounts of shRNAs can cause 
toxicity by interfering with the nuclear 
export of endogenous microRNAs 
[14]. Therefore, there is probably a 
limit to the number of siRNAs that 
can be effectively incorporated into 
any treatment. However, no published 
study has yet deﬁ  ned this limit.
In Vivo Delivery
The key obstacle to harnessing RNAi 
as a treatment is getting small RNAs 
into the cytoplasm of cells in vivo. 
This can be accomplished either by 
ﬁ  guring out a way to introduce small 
RNAs into cells as small molecule drugs 
(siRNA) or by using a plasmid or viral 
vector encoding an shRNA so that it 
will be processed like the endogenous 
microRNA precursors. The small 
molecule approach is best suited to 
short-term interventions, while gene 
therapy can potentially be used for 
long-term silencing via expression 
from an integrated transgene. To treat 
chronic infections, such as HIV or 
hepatitis C, a gene therapy strategy may 
make sense. However, concerns about 
safety and controlling gene expression 
make gene therapy less practical for 
immediate applications. 
Although small RNAs are not taken 
up by themselves into most cells in the 
body, the mucosal tissues of the body 
are an important exception. siRNAs 
mixed with a cationic lipid or even by 
themselves are efﬁ  ciently taken up by 
epithelial cells in the lung and vagina 
(Figure 2). In the genital tract, siRNAs 
are taken up deep into the lamina 
propria and the underlying stroma. 
The mechanism of uptake is not 
understood. Most viral infections are 
transmitted through mucosal surfaces, 
which provides the opportunity to 
intervene to prevent or treat viral 
infections during transmission or acute 
infection. In mice, local instillation 
of siRNAs targeting viral genes has 
shown striking protection against 
respiratory challenge with inﬂ  uenza, 
parainﬂ  uenza, and respiratory syncytial 
viruses [15–17]. The potential for 
siRNAs to treat viral infection has also 
been shown in primates challenged 
with the SARS coronavirus [18]. These 
encouraging animal experiments 
have led to the recent ﬁ  rst phase I 
study of siRNAs designed to treat viral 
infection. This study will begin to test 
the potential of RNAi for treatment 
of acute respiratory syncytial virus 
infection, a leading cause of death and 
serious morbidity in newborn children. 
Another mucosal tissue in which 
siRNAs have been shown to prevent 
viral infection is the female genital 
tract, where siRNAs targeting HSV-2 
genes protected mice from lethal HSV-
2 infection [19]. siRNA penetrated 
deep into the cervicovaginal tissue, and 
silencing persisted for over nine days. 
Mice were even protected when siRNA 
administration was delayed until 3 hours 
after viral challenge. This study suggests 
the possibility that a persistent antiviral 
state might be achieved in the genital 
tract to prevent sexual transmission, 
reactivation, or even oncogenesis for a 
variety of sexually transmitted viruses, 
such as HSV-2, HIV, and human 
papillomavirus. Topical application of 
antiviral siRNAs might also be effective 
at other localized and accessible sites 
of viral infection, such as the upper 
respiratory tract, eye (i.e., herpes 
keratitis), or skin (i.e., warts).
Although therapeutic delivery of 
siRNAs and silencing is clearly feasible 
at mucosal surfaces, systemic treatment 
of viruses that are disseminated or 
infect tissues deep within the body 
is more difﬁ  cult because of the 
challenge of efﬁ  ciently transducing 
cells in vivo. The main impediments 
to systemic uptake are the difﬁ  culty 
in traversing the cell membrane and 
the short half-life of intravenously 
injected siRNAs. Several potential 
solutions to the former problem have 
been described recently, including 
covalent conjugation of the passenger 
siRNA strand to a cell-targeting 
moiety, noncovalent association of 
siRNAs with cell-targeting molecules, 
and incorporation of siRNAs into 
liposomes or other nanoparticles 
[7,20,21]. The short half-life, which is 
caused by both rapid renal ﬁ  ltration 
and endogenous ribonuclease 
digestion, can be readily addressed by 
incorporating siRNAs into complexes 
or particles and by minor chemical 
modiﬁ  cations of the RNA backbone. 
Early studies showing inhibition of 
hepatitis viral replication required 
introducing siRNAs via a high-
volume bolus (termed hydrodynamic 
injection) that causes right-sided 
heart failure and is not suitable for 
clinical use. Although siRNAs can be 
effectively introduced into an organ, 
such as the liver or kidney, by selective 
catheterization of the principal vein 
draining the tissue [22], this is invasive 
and costly. Similarly, the intracerebral 
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injection approach used to deliver 
siRNAs targeting ﬂ  aviviruses is not 
likely to be used clinically. Intravenous 
low-pressure injection of chemically 
modiﬁ  ed siRNAs incorporated 
into modiﬁ  ed liposomes reduced 
replication of a hepatitis B virus 
replicon in mice [21]. This study was 
the ﬁ  rst demonstration of a systemic 
antiviral effect using a method of 
injection that is clinically feasible. 
It is likely that some of the other 
approaches developed for systemic 
siRNA delivery described above 
will also work for silencing viral 
infection. However, so far, achieving 
a noninvasive method to introduce 
siRNAs into the brain, as would be 
needed for treating viral encephalitis, 
remains an elusive goal.  
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